GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Debt-to-EBITDA

Zhaoke Ophthalmology (HKSE:06622) Debt-to-EBITDA : -0.81 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zhaoke Ophthalmology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$236.43 Mil. Zhaoke Ophthalmology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$23.91 Mil. Zhaoke Ophthalmology's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-321.50 Mil. Zhaoke Ophthalmology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zhaoke Ophthalmology's Debt-to-EBITDA or its related term are showing as below:

HKSE:06622' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.73   Med: -0.3   Max: -0.02
Current: -0.63

During the past 5 years, the highest Debt-to-EBITDA Ratio of Zhaoke Ophthalmology was -0.02. The lowest was -0.73. And the median was -0.30.

HKSE:06622's Debt-to-EBITDA is ranked worse than
100% of 275 companies
in the Biotechnology industry
Industry Median: 1.36 vs HKSE:06622: -0.63

Zhaoke Ophthalmology Debt-to-EBITDA Historical Data

The historical data trend for Zhaoke Ophthalmology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology Debt-to-EBITDA Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.30 -0.05 -0.02 -0.36 -0.73

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -0.13 -0.20 -0.27 -0.43 -0.81

Competitive Comparison of Zhaoke Ophthalmology's Debt-to-EBITDA

For the Biotechnology subindustry, Zhaoke Ophthalmology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhaoke Ophthalmology's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's Debt-to-EBITDA falls into.



Zhaoke Ophthalmology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zhaoke Ophthalmology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(236.433 + 23.914) / -358.61
=-0.73

Zhaoke Ophthalmology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(236.433 + 23.914) / -321.496
=-0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Zhaoke Ophthalmology  (HKSE:06622) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zhaoke Ophthalmology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhaoke Ophthalmology (HKSE:06622) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines